Phase I, Open Label, Dose Escalating Study to Investigate Safety and Tolerability of Intravesical Application of Trifunctional Anti-EPCAM x Anti-CD3 Antibody Catumaxomab in Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs Catumaxomab (Primary)
- Indications Bladder cancer; Carcinoma; Prostate cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Lindis Biotech
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 04 Apr 2022 Planned primary completion date changed from 30 Dec 2021 to 30 Dec 2022.
- 01 Apr 2021 New trial record